Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Drug Development, Not Conflicts, Dominates Gottlieb's Confirmation Hearing

Apr 10 2017

• By Derrick Gingery

Related Content

Gottlieb Promotes 'Bottom-Up' Review To Increase FDA Efficiency, Consistency

Apr 07 2017

Opioid Policy At US FDA: Gottlieb Seeks More Activist Role To Combat Abuse

Apr 07 2017

Novel Biologics In US Might Not Start Getting Suffixes Until August

Apr 05 2017

Gottlieb's Confirmation: He's Willing To Disagree With Trump, Sec. Price

Apr 06 2017

Gottlieb's Confirmation: Will Industry Ties Remain A Big Deal After The Hearing?

Apr 03 2017

Gottlieb Touts Devices For Pain Control To Help Solve Opioid Crisis

Apr 06 2017

FDA Passes The Buck On LDTs, But Floats Ideas

Jan 13 2017

Industry Communications With Payors: US FDA Okays Info On Investigational Drugs

Jan 19 2017

Califf Optimistic As He Departs US FDA

Jan 23 2017

Additional Topics

United States FDA Leadership Regulation BioPharmaceutical

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window